孟鲁斯特联合信必可都保治疗支气管哮喘疗效观察  

Observation of clinical therapeutic effect of symbicort turbuhaler and montelast on bronchial asthma

作　　者：谢伟国[1] 江莲[1] 谢诤[1] 张洁[1] 

机构地区：[1]东南大学附属江阴人民医院呼吸科,江苏江阴214400

出　　处：《临床肺科杂志》2014年第11期1966-1968,共3页Journal of Clinical Pulmonary Medicine

摘　　要：目的比较孟鲁斯特(顺尔宁)联合信必可都保与单用信必可都保治疗支气管哮喘的疗效差异。方法将60例支气管哮喘患者随机分两组,分别为单用信必可都保组和顺尔宁联合信必可都保组,治疗为期一年。比较治疗前后临床症状及肺功能的改变,在治疗结束后,随访1年。对其复发率进行评估。结果两组治疗前后临床症状及肺功能均有明显改善;顺尔宁联合信必可都保临床症状及肺功能改善更迅速,疗效更显著(P<0.05);1年随访,联合应用组复发率更低;两组间比较有统计学意义。结论顺尔宁联合信必可都保能更迅速,更有效的改善支气管哮喘的临床症状和肺功能,且复发率低。Objective To compare the efficiency of montelukast plus symbicort turbuhaler and symbicort turbuhaler only in the treatment of patients with bronchial asthma. Methods 60 patients with bronchial asthma were randomly divided into two groups. The treatment group was treated with Montelukast plus symbicort turbuhaler, and the control group was given symbicort turbuhaler only for one year. The pulmonary function and clinical symptoms before and after treatment were observed in the two groups, and the recurrence rate was observed strictly for 2 years. Results Before and after the treatment, their clinical symptoms and pulmonary function of the two groups were all improved, but the improvement was more pronounced in the treatment group than in the control group （ P 〈 0. 05 ）. The recurrence rate was lower in the treatment group than in the control group. Conclusion Montelukast plus symbicort turbuhaler can effectively improve their clinical symptoms and pulmonary function in the treatment of patients with bronchial asthma.

关 键 词：信必可都保 支气管哮喘 孟鲁斯特 

分 类 号：R562.25[医药卫生—呼吸系统]